Literature DB >> 20006519

A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent.

Yali Kong1, Kan Wang, Michael C Edler, Ernest Hamel, Susan L Mooberry, Mikell A Paige, Milton L Brown.   

Abstract

Chalcones represent a class of natural products that inhibits tubulin assembly. In this study we designed and synthesized boronic acid analogs of chalcones in an effort to compare biological activities with combretastatin A-4, a potent inhibitor of tubulin polymerization. Systematic evaluation of the positional effects of the carbonyl moiety towards inhibition of tubulin polymerization, cancer cell proliferation and angiogenesis revealed that placement of the carbonyl adjacent to the trimethoxybenzene A-ring resulted in more active compounds than when the carbonyl group was placed adjacent to the C-ring. Our study identified a boronic acid chalcone with inhibition towards 16 human cancer cell lines in the 10-200nM range, and another three cell lines with GI(50)-values below 10nM. Furthermore, this drug has significant anti-angiogenesis effects demonstrated by HUVEC tube formation and aortic ring assay. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20006519      PMCID: PMC2819108          DOI: 10.1016/j.bmc.2009.11.003

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  14 in total

Review 1.  Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin.

Authors:  Ernest Hamel
Journal:  Cell Biochem Biophys       Date:  2003       Impact factor: 2.194

2.  Potent antimitotic and cell growth inhibitory properties of substituted chalcones.

Authors:  S Ducki; R Forrest; J A Hadfield; A Kendall; N J Lawrence; A T McGown; D Rennison
Journal:  Bioorg Med Chem Lett       Date:  1998-05-05       Impact factor: 2.823

3.  Structure-based discovery of a boronic acid bioisostere of combretastatin A-4.

Authors:  Yali Kong; Jolanta Grembecka; Michael C Edler; Ernest Hamel; Susan L Mooberry; Michal Sabat; Jayson Rieger; Milton L Brown
Journal:  Chem Biol       Date:  2005-09

4.  Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice.

Authors:  Xiaolin Zi; Anne R Simoneau
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

5.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.

Authors:  A Monks; D Scudiero; P Skehan; R Shoemaker; K Paull; D Vistica; C Hose; J Langley; P Cronise; A Vaigro-Wolff
Journal:  J Natl Cancer Inst       Date:  1991-06-05       Impact factor: 13.506

6.  Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells.

Authors:  P Verdier-Pinard; J Y Lai; H D Yoo; J Yu; B Marquez; D G Nagle; M Nambu; J D White; J R Falck; W H Gerwick; B W Day; E Hamel
Journal:  Mol Pharmacol       Date:  1998-01       Impact factor: 4.436

7.  Synthetic chalcones as potential anti-inflammatory and cancer chemopreventive agents.

Authors:  Shen-Jeu Won; Cheng-Tsung Liu; Lo-Ti Tsao; Jing-Ru Weng; Horng-Huey Ko; Jih-Pyang Wang; Chun-Nan Lin
Journal:  Eur J Med Chem       Date:  2005-01       Impact factor: 6.514

8.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

9.  Chalcones: a new class of antimitotic agents.

Authors:  M L Edwards; D M Stemerick; P S Sunkara
Journal:  J Med Chem       Date:  1990-07       Impact factor: 7.446

10.  Anticancer and antioxidant activity of synthetic chalcones and related compounds.

Authors:  R J Anto; K Sukumaran; G Kuttan; M N Rao; V Subbaraju; R Kuttan
Journal:  Cancer Lett       Date:  1995-10-20       Impact factor: 8.679

View more
  17 in total

1.  Synthesis and biological evaluation of structurally diverse α-conformationally restricted chalcones and related analogues.

Authors:  Casey J Maguire; Graham J Carlson; Jacob W Ford; Tracy E Strecker; Ernest Hamel; Mary Lynn Trawick; Kevin G Pinney
Journal:  Medchemcomm       Date:  2019-06-04       Impact factor: 3.597

2.  Dietary chalcones with chemopreventive and chemotherapeutic potential.

Authors:  Barbora Orlikova; Deniz Tasdemir; Frantisek Golais; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2011-02-04       Impact factor: 5.523

3.  Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cells.

Authors:  Venkata Mahidhar Yenugonda; Yali Kong; Tushar B Deb; Yonghong Yang; Rebecca B Riggins; Milton L Brown
Journal:  Cancer Biol Ther       Date:  2012-08-01       Impact factor: 4.742

Review 4.  Molecular targeted approaches to cancer therapy and prevention using chalcones.

Authors:  Danielle D Jandial; Christopher A Blair; Saiyang Zhang; Lauren S Krill; Yan-Bing Zhang; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

5.  Cytotoxic 3,4,5-trimethoxychalcones as mitotic arresters and cell migration inhibitors.

Authors:  Lívia B Salum; Wanessa F Altei; Louise D Chiaradia; Marlon N S Cordeiro; Rafael R Canevarolo; Carolina P S Melo; Evelyn Winter; Bruno Mattei; Hikmat N Daghestani; Maria Cláudia Santos-Silva; Tânia B Creczynski-Pasa; Rosendo A Yunes; José A Yunes; Adriano D Andricopulo; Billy W Day; Ricardo J Nunes; Andreas Vogt
Journal:  Eur J Med Chem       Date:  2013-03-06       Impact factor: 6.514

6.  Cyclic chalcone analogue KRP6 as a potent modulator of cell proliferation: an in vitro study in HUVECs.

Authors:  Lenka Ivanova; Lenka Varinska; Martina Pilatova; Peter Gal; Peter Solar; Pal Perjesi; Karel Smetana; Alexander Ostro; Jan Mojzis
Journal:  Mol Biol Rep       Date:  2013-05-11       Impact factor: 2.316

7.  Novel hybrids derived from aspirin and chalcones potently suppress colorectal cancer in vitro and in vivo.

Authors:  Shan Lu; Obinna N Obianom; Yong Ai
Journal:  Medchemcomm       Date:  2018-08-27       Impact factor: 3.597

8.  Cytotoxicity of selected novel chalcone derivatives on human breast, lung and hepatic carcinoma cell lines.

Authors:  Maryam Nakhjavani; Afshin Zarghi; Farshad H Shirazi
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

9.  Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells.

Authors:  Yong Weon Yi; Hyo Jin Kang; Hee Jeong Kim; Yali Kong; Milton L Brown; Insoo Bae
Journal:  Oncotarget       Date:  2013-07

Review 10.  Targeting Oncogenic Mutant p53 for Cancer Therapy.

Authors:  Alejandro Parrales; Tomoo Iwakuma
Journal:  Front Oncol       Date:  2015-12-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.